{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:10:41Z","timestamp":1787508641288,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aspartyl-tRNA synthetase (DARS) is implicated in several cancers, but its role in BCR::ABL-negative JAK2V617F-positive myeloproliferative neoplasms (MPNs) is unclear. This study evaluated DARS expression in MPN subtypes and its associations with clinical parameters and survival.\u00a0Diagnostic bone marrow biopsies from 121 JAK2V617F-positive MPN patients (PV, n\u2009=\u200934; ET, n\u2009=\u200925; PMF, n\u2009=\u200954; MPN-U, n\u2009=\u20098) were stained on a Ventana BenchMark XT immunostainer using anti-DARS antibody (ABclonal A6574). DARS immunoreactive score (IRS) was determined by multiplying intensity (0\u20133) and percentage of positive cells (0\u20134). Inter-observer agreement was excellent (\u03ba\u2009=\u20090.89, 95% CI: 0.83\u20130.95). Patients were stratified using the cohort\u2019s median cutoff (IRS\u2009=\u20099) for survival analysis. Statistical tests included Kruskal-Wallis with effect sizes and multivariate Cox regression.\u00a0DARS IRS differed across subtypes (H\u2009=\u200914.19, p\u2009=\u20090.003, \u03b7\u00b2=0.10): PV median 9 with IQR (9\u201312), ET 9 (8\u201312), PMF 8 (6\u20139), and MPN-U 10.5 (6\u201312). PV vs. PMF differences: intensity p\u2009=\u20090.001 (r\u2009=\u20090.35), IRS p\u2009&lt;\u20090.001 (r\u2009=\u20090.38). DARS IRS correlated inversely with spleen size (\u03c1=\u20130.266, p\u2009=\u20090.003, 95% CI: \u2212\u20090.43 to \u2212\u20090.09), LDH (\u03c1=\u20130.194, p\u2009=\u20090.033), and fibrosis grade (\u03c1=\u20130.280, p\u2009=\u20090.002), and positively with hemoglobin (\u03c1\u2009=\u20090.308, p\u2009=\u20090.001, 95% CI: 0.13\u20130.47). High DARS expression independently predicted improved leukemia-free survival (LFS) (HR\u2009=\u20090.42, p\u2009=\u20090.007, 95% CI: 0.22\u20130.80) after adjusting for age, subtype, and fibrosis.\u00a0DARS is differentially expressed in MPN subtypes. Its association with enhanced LFS identifies DARS as a potential prognostic biomarker warranting validation in larger cohorts.<\/jats:p>","DOI":"10.1007\/s00277-026-06934-0","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:45:18Z","timestamp":1774579518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["DARS expression in JAK2V617F-positive myeloproliferative neoplasms: immunohistochemical analysis and clinical associations"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-0433","authenticated-orcid":false,"given":"Aya Mohamed Adel","family":"Arafat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5013-9586","authenticated-orcid":false,"given":"Heba Adel AbdEl","family":"Ghaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6435-5335","authenticated-orcid":false,"given":"Ahmed M.","family":"Khallaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufyan Ahmed Mokhtar","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2769-0502","authenticated-orcid":false,"given":"Mohamed Abdelkader","family":"Morad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1536-538X","authenticated-orcid":false,"given":"Shirihan Mahmoud Anwar","family":"Mahgoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"11","key":"6934_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u201328. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"issue":"5","key":"6934_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vainchenker W (2011) Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29(5):573\u2013582. https:\/\/doi.org\/10.1200\/JCO.2010.29.8711","journal-title":"J Clin Oncol"},{"issue":"1","key":"6934_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/145293","volume":"2015","author":"S Hermouet","year":"2015","unstructured":"Hermouet S, Bigot-Corbel E, Gardie B (2015) Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation. Mediators Inflamm 2015(1):145293. https:\/\/doi.org\/10.1155\/2015\/145293","journal-title":"Mediators Inflamm"},{"issue":"17","key":"6934_CR4","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779\u201390. https:\/\/doi.org\/10.1056\/NEJMoa051113","journal-title":"N Engl J Med"},{"issue":"5","key":"6934_CR5","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ajhg.2013.04.006","volume":"92","author":"RJ Taft","year":"2013","unstructured":"Taft RJ, Vanderver A, Leventer RJ, Damiani SA, Simons C, Grimmond SM, Miller D, Schmidt J, Lockhart PJ, Pope K, Ru K (2013) Mutations in DARS cause hypomyelination with brain stem and spinal cord involvement and leg spasticity. Am J Hum Genet 92(5):774\u2013780. https:\/\/doi.org\/10.1016\/j.ajhg.2013.04.006","journal-title":"Am J Hum Genet"},{"key":"6934_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00081","volume":"11","author":"D Fr\u00f6hlich","year":"2018","unstructured":"Fr\u00f6hlich D, Suchowerska AK, Voss C, He R, Wolvetang E, Von Jonquieres G, Simons C, Fath T, Housley GD, Klugmann M (2018) Expression pattern of the aspartyl-tRNA synthetase DARS in the human brain. Front Mol Neurosci 11:81. https:\/\/doi.org\/10.3389\/fnmol.2018.00081","journal-title":"Front Mol Neurosci"},{"issue":"10","key":"6934_CR7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nrc3124","volume":"11","author":"S Kim","year":"2011","unstructured":"Kim S, You S, Hwang D (2011) Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nat Rev Cancer 11(10):708\u2013718. https:\/\/doi.org\/10.1038\/nrc3124","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"6934_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040960","volume":"7","author":"YW Kim","year":"2012","unstructured":"Kim YW, Kwon C, Liu JL, Kim SH, Kim S (2012) Cancer association study of aminoacyl-tRNA synthetase signaling network in glioblastoma. PLoS One 7(8):e40960. https:\/\/doi.org\/10.1371\/journal.pone.0040960","journal-title":"PLoS One"},{"issue":"7","key":"6934_CR9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41556-024-01439-2","volume":"26","author":"N El-Hachem","year":"2024","unstructured":"El-Hachem N, Leclercq M, Susaeta Ruiz M, Vanleyssem R, Shostak K, K\u00f6rner PR, Capron C, Martin-Morales L, Roncarati P, Lavergne A, Blomme A (2024) Valine aminoacyl-tRNA synthetase promotes therapy resistance in melanoma. Nat Cell Biol 26(7):1154\u20131164. https:\/\/doi.org\/10.1038\/s41556-024-01439-2","journal-title":"Nat Cell Biol"},{"issue":"11","key":"6934_CR10","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1111\/jgh.15592","volume":"36","author":"X Gao","year":"2021","unstructured":"Gao X, Guo R, Li Y, Kang G, Wu Y, Cheng J, Jia J, Wang W, Li Z, Wang A, Xu H (2021) Contribution of upregulated aminoacyl-tRNA biosynthesis to metabolic dysregulation in gastric cancer. J Gastroenterol Hepatol 36(11):3113\u20133126. https:\/\/doi.org\/10.1111\/jgh.15592","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"6934_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/path.6046","volume":"259","author":"NB Halmai","year":"2023","unstructured":"Halmai NB, Carvajal-Carmona LG (2023) Advancing gastric cancer precision medicine with novel genomic screens. J Pathol 259(4):359\u2013361. https:\/\/doi.org\/10.1002\/path.6046","journal-title":"J Pathol"},{"issue":"10","key":"6934_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24691","volume":"36","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, You J, Wu C, Kang Y, Chen F, Chen L, Wu W (2022) High expression of DARS2 indicates poor prognosis in lung adenocarcinoma. J Clin Lab Anal 36(10):e24691. https:\/\/doi.org\/10.1002\/jcla.24691","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"6934_CR13","first-page":"818","volume":"13","author":"XS Liu","year":"2023","unstructured":"Liu XS, Pei ZJ, Zeng J, Zhang YH, Zhang Y, Gao Y, Liu C (2023) DARS2 is a prognostic biomarker and correlated with immune infiltrates and cuproptosis in lung adenocarcinoma. Am J Cancer Res 13(3):818\u2013835 PMID: 37034224; PMCID: PMC10077054","journal-title":"Am J Cancer Res"},{"issue":"12","key":"6934_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e11966","volume":"8","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang H, Sui Q, Li M, Liang J, Hu Z, Cheng Y, Zheng Y, Chen Z, Lin M, Wang H (2022) Identification and validation of the mitochondrial function related hub genes by unsupervised machine learning and multi-omics analyses in lung adenocarcinoma. Heliyon 8(12):e11966. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e11966","journal-title":"Heliyon"},{"key":"6934_CR15","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.12768","volume":"10","author":"M Zhang","year":"2022","unstructured":"Zhang M, Zhou Z, Liu Z, Liu F, Zhao C (2022) Exploring the potential biomarkers for prognosis of glioblastoma via weighted gene co-expression network analysis. PeerJ 10:e12768. https:\/\/doi.org\/10.7717\/peerj.12768","journal-title":"PeerJ"},{"issue":"9","key":"6934_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e19223","volume":"9","author":"NT Moldogazieva","year":"2023","unstructured":"Moldogazieva NT, Zavadskiy SP, Astakhov DV, Sologova SS, Margaryan AG, Safrygina AA, Smolyarchuk EA (2023) Differentially expressed non-coding RNAs and their regulatory networks in liver cancer. Heliyon 9(9):e19223. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e19223","journal-title":"Heliyon"},{"key":"6934_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-67067-w","volume":"14","author":"H Xiong","year":"2024","unstructured":"Xiong H, Liao M, Zhang H, Li Y, Bai J, Zhang J et al (2024) DARS expression in BCR::ABL1-negative myeloproliferative neoplasms and its association with the immune microenvironment. Sci Rep 14:16242. https:\/\/doi.org\/10.1038\/s41598-024-67067-w","journal-title":"Sci Rep"},{"key":"6934_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39591-7","volume":"9","author":"FG Liberante","year":"2019","unstructured":"Liberante FG, Lappin K, Barros EM, Vohhodina J, Savage KI, Mills KI (2019) Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability. Sci Rep 9:2849. https:\/\/doi.org\/10.1038\/s41598-019-39591-7","journal-title":"Sci Rep"},{"issue":"2","key":"6934_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/path.5980","volume":"258","author":"B Liu","year":"2022","unstructured":"Liu B, Katoh H, Komura D, Yamamoto A, Ochi M, Onoyama T, Abe H, Ushiku T, Seto Y, Suo J, Ishikawa S (2022) Functional genomics screening identifies aspartyl-tRNA synthetase as a novel prognostic marker and a therapeutic target for gastric cancers. J Pathol 258(2):106\u2013120. https:\/\/doi.org\/10.1002\/path.5980","journal-title":"J Pathol"},{"issue":"16","key":"6934_CR20","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood J Am Soc Hematol 124(16):2507\u20132513. https:\/\/doi.org\/10.1182\/blood-2014-05-579136","journal-title":"Blood J Am Soc Hematol"},{"issue":"6","key":"6934_CR21","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R (2017) Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129(6):667\u2013679. https:\/\/doi.org\/10.1182\/blood-2016-10-695940","journal-title":"Blood"},{"key":"6934_CR22","doi-asserted-by":"publisher","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","volume":"26","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kr\u00f6ger N, Thiele J, Buske C, ESMO Guidelines Committee (2015) Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v85\u201399. https:\/\/doi.org\/10.1093\/annonc\/mdv203","journal-title":"Ann Oncol"},{"issue":"7","key":"6934_CR23","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JK, Chen W (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"6934_CR24","first-page":"1","volume-title":"Diagnostic Immunohistochemistry","author":"CR Taylor","year":"2013","unstructured":"Taylor CR, Shi SR, Barr NJ, Wu N (2013) Techniques of immunohistochemistry: Principles, pitfalls, and standardization. Diagnostic Immunohistochemistry, 2nd edn. Academic, London, pp 1\u201342","edition":"2"},{"issue":"4","key":"6934_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5114\/pg.2022.120441","volume":"18","author":"T Lewandowski","year":"2022","unstructured":"Lewandowski T (2022) Personalized medicine in biomarker identification at their optimal cut-off selection. Gastroenterol Rev 18(4):402\u2013408. https:\/\/doi.org\/10.5114\/pg.2022.120441","journal-title":"Gastroenterol Rev"},{"issue":"12","key":"6934_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies J, Klauschen F, Sinn BV, Gyrffy B, Schmitt WD, Darb-Esfahani S, Denkert C (2012) Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One 7(12):e51862. https:\/\/doi.org\/10.1371\/journal.pone.0051862","journal-title":"PLoS One"},{"key":"6934_CR27","doi-asserted-by":"publisher","unstructured":"Jones JA, Wei N, Cui H, Shi Y, Fu G, Rauniyar N, Shapiro R, Morodomi Y, Berenst N, Dumitru CD, Kanaji S (2023) Nuclear translocation of an aminoacyl-tRNA synthetase may mediate a chronic \u201cintegrated stress response.\u201d Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2023.112632","DOI":"10.1016\/j.celrep.2023.112632"},{"issue":"5","key":"6934_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s12276-022-00765-5","volume":"54","author":"Y Sung","year":"2022","unstructured":"Sung Y, Yoon I, Han JM, Kim S (2022) Functional and pathologic association of aminoacyl-tRNA synthetases with cancer. Exp Mol Med 54(5):553\u2013566. https:\/\/doi.org\/10.1038\/s12276-022-00765-5","journal-title":"Exp Mol Med"},{"issue":"9","key":"6934_CR29","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1097\/MS9.0000000000003365","volume":"87","author":"S Bosco","year":"2025","unstructured":"Bosco S, Beniwal SS, Munshi SS, Calder\u00f3n DC, Jeong Y, Cacas AC, Kumar S, Dos Santos PH, Syed S, Dwivedi A, Einieh M (2025) Innovative strategies for mitochondrial dysfunction in myeloproliferative neoplasms a step toward precision medicine. Ann Med Surg (Lond) 87(9):5557\u20135568. https:\/\/doi.org\/10.1097\/MS9.0000000000003365","journal-title":"Ann Med Surg (Lond)"},{"issue":"4","key":"6934_CR30","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI82905","volume":"127","author":"L Gilles","year":"2017","unstructured":"Gilles L, Arslan AD, Marinaccio C, Wen QJ, Arya P, McNulty M, Yang Q, Zhao JC, Konstantinoff K, Lasho T, Pardanani A (2017) Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest 127(4):1316\u20131320. https:\/\/doi.org\/10.1172\/JCI82905","journal-title":"J Clin Invest"},{"key":"6934_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113264","author":"X Gu","year":"2023","unstructured":"Gu X, Li K, Zhang M, Chen Y, Zhou J, Yao C, Zang Y, He J, Wan J, Guo B (2023) Aspartyl-tRNA synthetase 2 orchestrates iron-sulfur metabolism in hematopoietic stem cells via fine-tuning alternative RNA splicing. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2023.113264","journal-title":"Cell Rep"},{"issue":"24","key":"6934_CR32","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","volume":"12","author":"HL Geyer","year":"2014","unstructured":"Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hern\u00e1ndez-Maraver D, D\u00f6hner K (2014) Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood, The Journal of the American Society of Hematology 12(24):3803\u201310. https:\/\/doi.org\/10.1182\/blood-2013-09-527903","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"6934_CR33","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1182\/blood-2025-5006","volume":"146","author":"H Xiong","year":"2025","unstructured":"Xiong H, Zhang H, Niu T, Li L, Zhang L (2025) DARS mediated M2 polarization of tumor associated macrophages drives MPN progression. Blood 146:5006. https:\/\/doi.org\/10.1182\/blood-2025-5006","journal-title":"Blood"},{"issue":"Suppl 1","key":"6934_CR34","doi-asserted-by":"publisher","first-page":"12180","DOI":"10.1182\/blood-2022-166992","volume":"140","author":"K Kirschner","year":"2022","unstructured":"Kirschner K, Rattigan K, Helgason V, Yan F (2022) Metabolic profiling of myeloproliferative neoplasms reveals subtype specific metabolic traits. Blood 140(Suppl 1):12180\u201312182. https:\/\/doi.org\/10.1182\/blood-2022-166992","journal-title":"Blood"},{"key":"6934_CR35","doi-asserted-by":"publisher","unstructured":"He F, Laranjeira AB, Kong T, Lin S, Ashworth KJ, Liu A, Lasky NM, Fisher DA, Cox MJ, Fulbright MC, Antunes-Heck L (2024) Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI172256","DOI":"10.1172\/JCI172256"},{"key":"6934_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3324\/haematol.11653","volume":"93","author":"E Antonioli","year":"2008","unstructured":"Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L, Santini V, Bosi A (2008) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 93:41\u201348. https:\/\/doi.org\/10.3324\/haematol.11653","journal-title":"Haematologica"},{"issue":"4","key":"6934_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5045\/br.2021.2021089","volume":"56","author":"AJ Lee","year":"2021","unstructured":"Lee AJ, Kim SG, Nam JY, Yun J, Ryoo HM, Bae SH (2021) Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden. Blood Res 56(4):259\u2013265. https:\/\/doi.org\/10.5045\/br.2021.2021089","journal-title":"Blood Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06934-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06934-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06934-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:57:32Z","timestamp":1781643452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06934-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6934"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06934-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Beni-Suef University Ethics Committee (approval number: FMBSUREC\/01072025\/Khalaf). Written informed consent was obtained from all participants before enrolment. All procedures involving human participants were performed in accordance with the ethical standards of the institutional research committees and with the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Clinical trial number"}},{"value":"Written informed consent for publication was obtained from all individual participants included in this study. The authors affirm that informed consent for publication was obtained from all patients whose tissue samples were used in this research. All histopathological images and clinical data presented have been de-identified to ensure patient confidentiality and privacy Data Availability The datasets used and analyzed in the current study are available from the corresponding author upon reasonable request, subject to appropriate ethics approval.\u00a0","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}